Driehaus Capital Management’s Hemab Therapeutics COAG Stock Holding History
Bought
Maintained
Sold
Other funds holding COAG
SL
Driehaus Capital Management's COAG Position: Q3 2026 in Review
Driehaus Capital Management reduced its Hemab Therapeutics (COAG) stake by 1.1% in Q3 2026, selling an estimated $335K and leaving 708,166 shares worth $21.8M. The position accounts for 0.15% of the portfolio, ranked #191.
Driehaus Capital Management first reported a position in COAG in Q2 2026 and has held it in 2 quarters since. The position peaked at $26.3M in Q2 2026. 89 funds tracked by Wall St. Rank hold COAG as of Q3 2026.
- Driehaus Capital Management held 708,166 shares of Hemab Therapeutics worth $21.8M as of Q3 2026.
- Driehaus Capital Management sold 7,625 Hemab Therapeutics shares in Q3 2026, an estimated $335K.
- Hemab Therapeutics made up 0.15% of Driehaus Capital Management's portfolio in Q3 2026, its #191 holding.
- Driehaus Capital Management first reported a position in Hemab Therapeutics in Q2 2026 and has held it in 2 quarters since.
- Driehaus Capital Management's Hemab Therapeutics position peaked at $26.3M in Q2 2026.
- 89 funds tracked by Wall St. Rank held Hemab Therapeutics as of Q3 2026.
Based on Driehaus Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.